Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
Standard
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. / Scheid, C; de Wreede, L; van Biezen, A; Koenecke, C; Göhring, G; Volin, L; Maertens, J; Finke, J; Passweg, J; Beelen, D; Cornelissen, J J; Itälä-Remes, M; Chevallier, P; Russell, N; Petersen, E; Milpied, N; Richard Espiga, C; Peniket, A; Sierra, J; Mufti, G; Crawley, C; Veelken, J H; Ljungman, P; Cahn, J Y; Alessandrino, E P; de Witte, T; Robin, M; Kröger, N.
in: BONE MARROW TRANSPL, Jahrgang 52, Nr. 11, 11.2017, S. 1519-1525.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
AU - Scheid, C
AU - de Wreede, L
AU - van Biezen, A
AU - Koenecke, C
AU - Göhring, G
AU - Volin, L
AU - Maertens, J
AU - Finke, J
AU - Passweg, J
AU - Beelen, D
AU - Cornelissen, J J
AU - Itälä-Remes, M
AU - Chevallier, P
AU - Russell, N
AU - Petersen, E
AU - Milpied, N
AU - Richard Espiga, C
AU - Peniket, A
AU - Sierra, J
AU - Mufti, G
AU - Crawley, C
AU - Veelken, J H
AU - Ljungman, P
AU - Cahn, J Y
AU - Alessandrino, E P
AU - de Witte, T
AU - Robin, M
AU - Kröger, N
PY - 2017/11
Y1 - 2017/11
N2 - The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P<0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P<0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.Bone Marrow Transplantation advance online publication, 11 September 2017; doi:10.1038/bmt.2017.171.
AB - The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55.0 months, intermediate 19.7 months, high 13.5 months, very high 7.8 months (P<0.001). In a multivariate Cox model the following parameters were significant risk factors for OS: IPSS-R, graft source, age and prior treatment. Median relapse free survival also showed significant differences according to IPSS-R: very low: 23.6 months, low: 24.8 months, intermediate 10.6 months, high 7.9 months, very high 5.5 months (P<0.001). Multivariate risk factors for relapse-free survival (RFS) were: IPSS-R, reduced intensity conditioning, graft source and prior treatment. A trend for an increased relapse incidence was noted for very high risk IPSS-R. We conclude that the IPSS-R at transplant is a useful prognostic score for predicting OS and RFS after transplantation, capturing both disease evolution and response to prior treatment before transplant.Bone Marrow Transplantation advance online publication, 11 September 2017; doi:10.1038/bmt.2017.171.
KW - Journal Article
U2 - 10.1038/bmt.2017.171
DO - 10.1038/bmt.2017.171
M3 - SCORING: Journal article
C2 - 28892084
VL - 52
SP - 1519
EP - 1525
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 11
ER -